PMID- 28527918
OWN - NLM
STAT- MEDLINE
DCOM- 20180607
LR  - 20240327
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Print)
IS  - 0163-7258 (Linking)
VI  - 179
DP  - 2017 Nov
TI  - Cytochrome P450 eicosanoids in cerebrovascular function and disease.
PG  - 31-46
LID - S0163-7258(17)30123-7 [pii]
LID - 10.1016/j.pharmthera.2017.05.004 [doi]
AB  - Cytochrome P450 eicosanoids play important roles in brain function and disease 
      through their complementary actions on cell-cell communications within the 
      neurovascular unit (NVU) and mechanisms of brain injury. Epoxy- and 
      hydroxyeicosanoids, respectively formed by cytochrome P450 epoxygenases and 
      omega-hydroxylases, play opposing roles in cerebrovascular function and in 
      pathological processes underlying neural injury, including ischemia, 
      neuroinflammation and oxidative injury. P450 eicosanoids also contribute to 
      cerebrovascular disease risk factors, including hypertension and diabetes. We 
      summarize studies investigating the roles P450 eicosanoids in cerebrovascular 
      physiology and disease to highlight the existing balance between these important 
      lipid signaling molecules, as well as their roles in maintaining neurovascular 
      homeostasis and in acute and chronic neurovascular and neurodegenerative 
      disorders.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Davis, Catherine M
AU  - Davis CM
AD  - Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science 
      University, Portland, OR 97239, United States; The Knight Cardiovascular 
      Institute, Oregon Health & Science University, Portland, OR 97239, United States.
FAU - Liu, Xuehong
AU  - Liu X
AD  - The Knight Cardiovascular Institute, Oregon Health & Science University, 
      Portland, OR 97239, United States.
FAU - Alkayed, Nabil J
AU  - Alkayed NJ
AD  - Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science 
      University, Portland, OR 97239, United States; The Knight Cardiovascular 
      Institute, Oregon Health & Science University, Portland, OR 97239, United States. 
      Electronic address: alkayedn@ohsu.edu.
LA  - eng
GR  - R01 NS044313/NS/NINDS NIH HHS/United States
GR  - R01 NS070837/NS/NINDS NIH HHS/United States
GR  - R21 AG043857/AG/NIA NIH HHS/United States
GR  - RF1 AG058273/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170518
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Eicosanoids)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
SB  - IM
MH  - Animals
MH  - Brain/*metabolism
MH  - Cerebrovascular Disorders/*metabolism
MH  - Cytochrome P-450 Enzyme System/*metabolism
MH  - Eicosanoids/*metabolism
MH  - Humans
MH  - Risk Factors
PMC - PMC5651205
MID - NIHMS879151
OTO - NOTNLM
OT  - Cerebrovascular
OT  - Cytochrome P450
OT  - EETs
OT  - HETEs
OT  - Neurovascular unit
OT  - sEH
COIS- Conflict of Interest Statement The authors declare that there are no conflicts of 
      interest.
EDAT- 2017/05/22 06:00
MHDA- 2018/06/08 06:00
PMCR- 2018/11/01
CRDT- 2017/05/22 06:00
PHST- 2017/05/22 06:00 [pubmed]
PHST- 2018/06/08 06:00 [medline]
PHST- 2017/05/22 06:00 [entrez]
PHST- 2018/11/01 00:00 [pmc-release]
AID - S0163-7258(17)30123-7 [pii]
AID - 10.1016/j.pharmthera.2017.05.004 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2017 Nov;179:31-46. doi: 10.1016/j.pharmthera.2017.05.004. Epub 
      2017 May 18.